
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/8871/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:09:19 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  
                    <script>var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"543865",ustr:"",originlat:"0",clientrtt:"606",ghostip:"23.62.181.15",ipv6:false,pct:"10",clientip:"105.119.6.83",requestid:"379bd357",region:"42877",protocol:"",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"379bd357",ai:"505979",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}</script>
                    </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--8871 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--8871 block--content--website-notice-block block--content--website-notice-block--8871 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--8871 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--8871 block--content--system-main-block block--content--system-main-block--8871 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--8871 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001104659-22-072136.rtf%3b%20filename_%3dUTF-8%27%270001104659-22-072136.rtf" type="application/rtf" title="0001104659-22-072136.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001104659-22-072136.pdf%3b%20filename_%3dUTF-8%27%270001104659-22-072136.pdf" type="application/pdf" title="0001104659-22-072136.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001104659-22-072136.xls%3b%20filename_%3dUTF-8%27%270001104659-22-072136.xls" type="application/vnd.ms-excel" title="0001104659-22-072136.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001104659-22-072136.html" type="application/octet-stream" title="0001104659-22-072136-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srrk="http://scholarrock.com/20220617">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />

                    <script>var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"543865",ustr:"",originlat:"0",clientrtt:"606",ghostip:"23.62.181.15",ipv6:false,pct:"10",clientip:"105.119.6.83",requestid:"379bd357",region:"42877",protocol:"",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"379bd357",ai:"505979",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}</script>
                    </head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_srrk_scholarrock.com_20220617 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20220617_20220617 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001727196 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityCentralIndexKey">0001727196</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="#srrk-20220617.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-06-17to2022-06-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-17</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
Washington, D.C. 20549</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_907_edei--DocumentType_c20220617__20220617_zadsFDaqiy41"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CURRENT REPORT</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of earliest event Reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20220617__20220617_ze7mIgrR2Zpc"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 17, 2022</ix:nonNumeric></span>
</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20220617__20220617_zngrn5f7S0hh"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityRegistrantName">Scholar Rock Holding Corporation</ix:nonNumeric></span></b></span><br />
(Exact Name of Registrant as Specified in Charter)</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220617__20220617_z0C3gII7o8Xj"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 34%; text-align: center"><b><span id="xdx_909_edei--EntityFileNumber_c20220617__20220617_zk81Xf4xyVJ1"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityFileNumber">001-38501</ix:nonNumeric></span></b></td>
    <td style="width: 33%; text-align: center"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220617__20220617_zl5sh2PLFRfj"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityTaxIdentificationNumber">82-3750435</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction of <br />
Incorporation)</td>
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">(I.R.S. Employer Identification <br />
Number)</td></tr>
<tr style="vertical-align: top">
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220617__20220617_zNecYn27RnTf"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityAddressAddressLine1">301 Binney Street</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20220617__20220617_zKqxDtTHpKv8"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityAddressAddressLine2">3rd Floor</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20220617__20220617_zaLMESNxIpHc"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20220617__20220617_zZPh84repHMi"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20220617__20220617_zgmH6jY7JZv"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">(Address of Principal Executive Offices) (Zip Code)</td></tr>
</table>
<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(<span id="xdx_902_edei--CityAreaCode_c20220617__20220617_zSm32A21qPWl"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:CityAreaCode">857</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20220617__20220617_zQwxYLXdGRh6"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:LocalPhoneNumber">259-3860</ix:nonNumeric></span></b></span></p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant's telephone
number, including area code)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or
former address, if changed since last report)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #000000; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Wingdings"><span id="xdx_906_edei--WrittenCommunications_c20220617__20220617_zBgRd8TnQZ31"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_907_edei--SolicitingMaterial_c20220617__20220617_zM7iM9VxC40l"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20220617__20220617_zWY8A723DWhl"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20220617__20220617_zfWYTmLOwo53"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which <br />
registered</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20220617__20220617_zWQY7zQbSvfl"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20220617__20220617_zu3tPBG9UGLc"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" name="dei:TradingSymbol">SRRK</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20220617__20220617_zT6RsIQ2L199">
    <ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>


<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR &#167;240.12b-2). Emerging growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220617__20220617_znu5m38Ioe69" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityExTransitionPeriod_c20220617__20220617_zxKuwI11E3Sk"><ix:nonNumeric contextRef="From2022-06-17to2022-06-17" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.02 Termination of a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock Holding Corporation (the &#8220;Company&#8221;) previously
entered into an Open Market Sale Agreement<sup>SM</sup> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;)
on March 9, 2021, pursuant to which the Company was able to issue and sell from time to time in an &#8220;at-the-market&#8221; offering
shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;). As of June 16, 2022, 500,000
shares of Common Stock have been issued and sold under the Sale Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 16, 2022, the Company provided notice to the Sales Agent that
it was terminating the Sale Agreement, effective immediately. The Sale Agreement provided for termination thereof by either party upon
ten (10) calendar days&#8217; prior written notice to the other party; however, the Sales Agent has waived such ten (10) day notice requirement.
The Company will not incur any early termination penalties in connection with the termination of the Sale Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On June
17, 2022, the Company issued a press release announcing positive 24-month topline results from its TOPAZ Phase 2 clinical trial for apitegromab.
A copy of the press release is attached hereto as Exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2022, the Company will host a conference
call and webcast at 8:30 am ET to discuss the 24-month topline results from the TOPAZ Phase 2 clinical trial. A copy of the presentation
slides to be used by the Company during the conference call and webcast is attached hereto as Exhibit 99.2. A live webcast of the conference
call may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at http://investors.scholarrock.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The information in this report furnished pursuant
to Item 7.01 and Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the
general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. It may only
be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing
specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this report.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">TOPAZ Phase 2 Clinical Trial Update</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On June
17, 2022, the Company announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of
treatment, which support sustained and continued improvement with apitegromab for non-ambulatory patients with Types 2 and 3 SMA receiving
an SMN therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TOPAZ evaluated apitegromab across a broad age range (2-21 years) of
patients with Types 2 and 3 SMA. All 35 non-ambulatory patients (Cohorts 2 and 3) and 12 of 23 ambulatory patients (Cohort 1) were receiving
nusinersen maintenance therapy. The primary efficacy endpoint for the non-ambulatory population was mean change from baseline in HFMSE.
Additional endpoints included mean change from baseline in RULM, an assessment specifically designed for upper limb function in patients
with SMA. The HFMSE is a validated measure for the assessment of gross motor function in SMA, while the RULM is validated to evaluate
upper limb motor performance by evaluating tasks which correspond to the ability to perform various everyday activities with their hands
and arms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For this 24-month evaluation, an observed case analysis was conducted,
which pooled all the non-ambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis
population included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort
3 who switched from 2 mg/kg to 20 mg/kg in Year 2) and did not exclude any patients who had missed apitegromab doses due to study site
access restrictions from COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-ambulatory patients</b> (age range of 2 to 21 years old) with
valid HFMSE assessments had sizable, sustained gains in HFMSE scores at 24 months from baseline (<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242424">p</span>rior
to first dose of apitegromab), while RULM scores continued to increase at 24 months. The mean change from baseline results for non-ambulatory
patients showed:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="border: black 1pt solid; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#160;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><b>12</b>-<b>Month Data</b></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: White"><b>24-Month Data</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: White"><b>Pooled non-ambulatory
    pts</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: White"><b>24-Month Data</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: White"><b>*excluding pts w/scoliosis
    surgery</b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mean Change from Baseline in </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>HFMSE </b>(95% CI)</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>3.6 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.2, 6.0)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=32</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4.0 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.5, 6.5)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=29</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4.4 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 2.0, 6.9)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=28</p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mean Change from Baseline in </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>RULM </b>(95% CI)</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>1.3 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 0.2, 2.3)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=31</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>1.9 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 0.8, 3.0)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=33</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2.3 points </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.2, 3.4)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=30</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*<i>Three patients in the non-ambulatory group underwent scoliosis
surgery in year 2, which has been reported to negatively impact HFMSE scores for a considerable period afterwards. This analysis excluded
post-surgery data of these patients.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dose response continued to be observed across the 24 months of apitegromab
administration based upon HFMSE scores and pharmacodynamic data (target engagement as measured by serum latent myostatin concentrations),
with signs that that there may be further HFMSE increases as non-ambulatory patients originally receiving the low dose switched to the
high dose treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data at 24-months for ambulatory patients with Type 3 SMA (Cohort 1)
suggest stability of Revised Hammersmith Scale (RHS) scores in patients receiving 20 mg/kg of apitegromab and nusinersen. The mean RHS
change from baseline at 24-months was &#45;0.7 points (95% CI: -3.1, 1.7) for the apitegromab and nusinersen subgroup (n=10) and &#45;2.8
points (95% CI: -8.4, 2.8) for the apitegromab monotherapy subgroup (n=11). A subset of individuals in Cohort 1(n=21) had RHS improvements,
as reflected by 42.9% (9/21) and 23.8% (5/21) of patients having &#8805;1-point and &#8805;3-point RHS increases from baseline at 24 months
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the 55 patients who completed the 24-month TOPAZ extension period,
54 have opted to continue treatment in the 36-month extension period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Consistent with the 12-month safety data, no serious&#160;safety
risks were identified as part of the analysis of the cumulative 24-month data. The incidence and severity of adverse events were consistent
with the underlying patient population and background therapy. The five most common treatment-emergent adverse events (TEAEs) were headache,
pyrexia, upper respiratory&#160;tract infection, cough, and nasopharyngitis.&#160;No&#160;deaths or serious adverse reactions have been
observed with apitegromab.&#160; A total of 14 serious TEAEs have been reported over the 24-month treatment period, all assessed by the
respective trial investigator as unrelated to apitegromab.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: Black 1pt solid; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>No.</b></p></td>
    <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 92%; font-size: 10pt"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="font-size: 10pt"><a href="#tm2218780d1_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><a href="#tm2218780d1_ex99-1.htm" style="-sec-extract: exhibit">Press Release issued by Scholar Rock Holding Corporation, dated June 17, 2022</a></td></tr>
  <tr>
    <td style="font-size: 10pt"><a href="#tm2218780d1_ex99-2.htm" style="-sec-extract: exhibit">99.2</a></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><a href="#tm2218780d1_ex99-2.htm" style="-sec-extract: exhibit">Presentation Slide Deck</a></td></tr>
  <tr>
    <td style="font-size: 10pt">104</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>Scholar Rock Holding Corporation</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: June 17, 2022</td>
    <td>By:</td>
    <td style="border-bottom: Black 1pt solid">/s/ Junlin Ho</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Junlin Ho</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>General Counsel and Corporate Secretary</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0">&#160;</p>



<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

</body>

<!-- Mirrored from investors.scholarrock.com/node/8871/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:09:19 GMT -->
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbTOH9judOgQp8gQ8bZsUYpbM9L690i+pXVDDIGQnPPlCBGKjFa6RobTosjhgE1bK4dQ4BkZTYneka43CfhZ4EVbx8q4bv2BKXkGPTMdjEt/75x3bbFKQM6GMh5GEmScTGKYb0Xw1VMyZ12hcVrVoEwFe6aWNTrFr/7DQT3JUPPqko7IVpNJYDSQvfyGSI4i2NFdPYivFvI8FUHYVSAyplv7jblZRw0sa2x8lu3Rfwcf3fxJGQ== -->
</XBRL>
<div><a name="tm2218780d1_ex99-1.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>

                    <script>var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"543865",ustr:"",originlat:"0",clientrtt:"606",ghostip:"23.62.181.15",ipv6:false,pct:"10",clientip:"105.119.6.83",requestid:"379bd357",region:"42877",protocol:"",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"379bd357",ai:"505979",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}</script>
                    </HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Positive Phase 2 Topaz Trial Extension Data
Demonstrate Sizable and Sustained Motor Function <BR>
Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and
3 Spinal <BR>
Muscular Atrophy (SMA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">-&nbsp;&nbsp;&nbsp;<I>Sizable and sustained improvement in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores observed
at 24 months </I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>-&nbsp;&nbsp;&nbsp;Substantial increase in Revised Upper Limb Module (RULM) scores observed
at 24 months </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><I>-&nbsp;&nbsp;&nbsp;No serious safety risks identified over 24 months</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">-&nbsp;&nbsp;&nbsp;<I>Enrollment progressing in pivotal Phase 3 SAPPHIRE registrational trial</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">-&nbsp;&nbsp;&nbsp;<I>Scholar Rock&nbsp;to host webcast today at&nbsp;8:30 a.m. ET</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CAMBRIDGE, Mass.,&nbsp;June 17, 2022 (BUSINESS WIRE) --&nbsp;Scholar
Rock&nbsp;(NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein
growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes
after 24-months of treatment, which support sustained and continued improvement with apitegromab for non-ambulatory patients with Types
2 and 3 SMA receiving an SMN therapy. Detailed results are being presented by Thomas Crawford, M.D. of&nbsp;Johns Hopkins Medicine and
the lead principal investigator of the TOPAZ trial, during a podium presentation at the Cure SMA Research &amp; Clinical Care Meeting
today at 11:20 a.m. PST.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;The 24-month results provide long-term data and evidence, underscoring
the findings of the 12-month primary treatment period of the TOPAZ trial in which patients receiving apitegromab experienced sizable motor
function gains,&rdquo; said George Nomikos, M.D., Ph.D., Senior Vice President of Clinical Sciences, Head of Muscle Therapeutic Area of
Scholar Rock. &ldquo;This durability and continued increase in motor function support the transformative potential of apitegromab for
patients suffering with SMA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These data support apitegromab&rsquo;s potential to meaningfully
improve the lives of non-ambulatory patients with Types 2 and 3 SMA,&rdquo; said Nagesh Mahanthappa, Ph.D., Founding Chief Executive Officer
 &amp; President of Scholar Rock. &ldquo;As a company, we are dedicated to the SMA community and are urgently enrolling patients in our
ongoing pivotal Phase 3 SAPPHIRE trial.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TOPAZ evaluated apitegromab across a broad age range (2-21 years) of
patients with Types 2 and 3 SMA. All 35 non-ambulatory patients (Cohorts 2 and 3) and 12 of 23 ambulatory patients (Cohort 1) were receiving
nusinersen maintenance therapy. The primary efficacy endpoint for the non-ambulatory population was mean change from baseline in HFMSE.
Additional endpoints included mean change from baseline in RULM, an assessment specifically designed for upper limb function in patients
with SMA. The HFMSE is a validated measure for the assessment of gross motor function in SMA, while the RULM is validated to evaluate
upper limb motor performance by evaluating tasks which correspond to the ability to perform various everyday activities with their hands
and arms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For this 24-month evaluation, an observed case analysis was conducted,
which pooled all the non-ambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis
population included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort
3 who switched from 2 mg/kg to 20 mg/kg in Year 2) and did not exclude any patients who had missed apitegromab doses due to study site
access restrictions from COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-ambulatory patients</B> (age range of 2 to 21 years old) with
valid HFMSE assessments had sizable, sustained gains in HFMSE scores at 24 months from baseline (<FONT STYLE="font-size: 10pt; color: #242424">p</FONT>rior
to first dose of apitegromab), while RULM scores continued to increase at 24 months. The mean change from baseline results for non-ambulatory
patients showed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="background-color: White; width: 36%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: White; width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12</B>-<B>Month Data</B></FONT></TD>
    <TD STYLE="background-color: White; width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>24-Month Data</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pooled non<BR>
-ambulatory pts</B></P></TD>
    <TD STYLE="background-color: White; width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>24-Month Data</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>*excluding pts<BR>
 w/scoliosis surgery</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mean Change from Baseline in </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HFMSE </B>(95% CI)</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3.6 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.2, 6.0)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=32</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4.0 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.5, 6.5)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=29</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4.4 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 2.0, 6.9)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=28</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mean Change from Baseline in </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RULM </B>(95% CI)</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1.3 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 0.2, 2.3)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=31</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1.9 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 0.8, 3.0)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=33</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2.3 points </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(95% CI: 1.2, 3.4)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N=30</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*<I>Three patients in the non-ambulatory group underwent scoliosis
surgery in year 2, which has been reported to negatively impact HFMSE scores for a considerable period afterwards<FONT STYLE="font-size: 10pt"><B><SUP>1</SUP></B></FONT>.
This analysis excluded post-surgery data of these patients.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dose response continued to be observed across the 24 months of apitegromab
administration based upon HFMSE scores and pharmacodynamic data (target engagement as measured by serum latent myostatin concentrations),
with signs that that there may be further HFMSE increases as non-ambulatory patients originally receiving the low dose switched to the
high dose treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Data at 24-months for ambulatory patients</B> with Type 3 SMA (Cohort
1) suggest stability of Revised Hammersmith Scale (RHS) scores in patients receiving 20 mg/kg of apitegromab and nusinersen. The mean
RHS change from baseline at 24-months was &#45;0.7 points (95% CI: -3.1, 1.7) for the apitegromab and nusinersen subgroup (n=10) and &#45;2.8
points (95% CI: -8.4, 2.8) for the apitegromab monotherapy subgroup (n=11). A subset of individuals in Cohort 1(n=21) had RHS improvements,
as reflected by 42.9% (9/21) and 23.8% (5/21) of patients having &#8805;1-point and &#8805;3-point RHS increases from baseline at 24 months
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the 55 patients who completed the 24-month TOPAZ extension period,
54 have opted to continue treatment in the 36-month extension period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consistent with the 12-month safety data, no serious&nbsp;safety
risks were identified as part of the analysis of the cumulative 24-month data. The incidence and severity of adverse events were
consistent with the underlying patient population and background therapy. The five most common treatment-emergent adverse events
(TEAEs) were headache, pyrexia, upper respiratory&nbsp;tract infection, cough, and nasopharyngitis.&nbsp;No&nbsp;deaths or serious
adverse reactions have been observed with apitegromab.&nbsp; A total of 14 serious TEAEs have been reported over the 24-month
treatment period, all assessed by the respective trial investigator as unrelated to apitegromab.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <FONT STYLE="background-color: white">Dunaway Young, Sally
et al. &lsquo;Scoliosis Surgery Significantly Impacts Motor Abilities in Higher-functioning Individuals with Spinal Muscular Atrophy&rsquo;.
<I>Journal of Neuromuscular Disease.</I> 1 Jan. 2020: 183&ndash;192.</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #201F1E">Details of the
podium presentation at </FONT>SMA Research &amp; Clinical Care Meeting <FONT STYLE="color: #201F1E">are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>Title</B>: TOPAZ Extension:
24-Month Efficacy and Safety of Apitegromab in Patients with Later-Onset Spinal Muscular Atrophy (Type 2 and Type 3 SMA)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>Presenter</B>: Thomas Crawford,
M.D., lead principal investigator of the TOPAZ trial and Professor of Neurology and Pediatrics; Johns Hopkins University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>Clinical Drug Development
Session: </B>June 17 at 11:20 - 11:40 a.m. PST (Abstract #28)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Conference Call/Webcast:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Scholar Rock will host a conference call
and audio webcast to discuss topline 24-month data from the Phase 2 TOPAZ clinical trial on June 17, 2022 at 8:30 a.m. Eastern Time. To
participate in the call, please dial 833-519-1308 (domestic) or 914-800-3874 (international) and refer to conference ID: 6495684. A webcast
of the call will also be available on the Investors &amp; Media section of the Scholar Rock website at&nbsp;http://investors.scholarrock.com.
An archived replay of the webcast will be available on Scholar Rock&rsquo;s website at:&nbsp;https://scholarrock.com/&nbsp;for approximately
180 days following the presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Phase 2 TOPAZ Trial </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The TOPAZ trial is an ongoing proof-of-concept, open-label phase 2
trial evaluating the safety and efficacy of apitegromab in patients with Types 2 and 3 SMA. In the main treatment period, patients were
dosed intravenously every four weeks as monotherapy or with nusinersen, an approved SMN therapy. The trial enrolled 58 patients in the
U.S. and Europe. The primary efficacy endpoints were mean change from baseline in Revised Hammersmith Scale (RHS) score at 12 months for
the ambulatory population (Cohort 1), and mean change from baseline in HFMSE score at 12 months for non-ambulatory population (Cohorts
2 and 3). The trial also includes multiple 12-month extension periods designed to evaluate longer-term patient outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Phase 3 SAPPHIRE Trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAPPHIRE is an ongoing randomized, double-blind, placebo-controlled,
phase 3 clinical trial evaluating the safety and efficacy of apitegromab in non-ambulatory patients with Types 2 and 3 SMA who are receiving
SMN therapy (either nusinersen or risdiplam). Approximately 156 patients aged 2-12 years old are anticipated to be enrolled in the main
efficacy population. These patients will be randomized 1:1:1 to receive for 12-months either apitegromab 10 mg/kg, apitegromab 20 mg/kg,
or placebo by intravenous (IV) infusion every 4 weeks. An exploratory population of approximately 48 patients aged 13-21 years old will
also separately be evaluated. These patients will be randomized 2:1 to receive either apitegromab 20 mg/kg or placebo. In this subpopulation
of older individuals with SMA, the safety and tolerability of apitegromab will be characterized, and efficacy will also be evaluated
in an exploratory, nonpowered manner. SAPPHIRE is expected to enroll 55 sites in the U.S. and Europe. For more information about SAPPHIRE,
visit www.clinicaltrials.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Apitegromab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Apitegromab is a selective inhibitor of the
activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA).
Myostatin, a member of the TGF&#946; superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence
of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes
that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with
SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the
European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for
the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any
use by the FDA or any other regulatory agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About SMA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder
that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States and Europe.
It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness.
The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor neuron) protein, essential for the
survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics
that address the underlying SMA genetic defect, via SMN-dependent pathways, there continues to be a high unmet need for therapeutics that
directly address muscle function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;Scholar Rock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock&nbsp;is a clinical-stage biopharmaceutical company focused
on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors
plays a fundamental role.&nbsp;Scholar Rock&nbsp;is creating a pipeline of novel product candidates with the potential to transform the
lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&rsquo;s
approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a&nbsp;proprietary platform&nbsp;for
the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.
By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated
with inhibiting growth factors for therapeutic effect.&nbsp;Scholar Rock&nbsp;believes its focus on biologically validated growth factors
may facilitate a more efficient development path. For more information, please visit&nbsp;www.ScholarRock.com&nbsp;or follow&nbsp;Scholar
Rock&nbsp;on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/). Investors and others should note that
we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts
and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could
be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that
we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock<SUP>&reg;</SUP> is a registered trademark of Scholar
Rock, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &quot;forward-looking statements&quot;
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar
Rock&rsquo;s future expectations, plans and prospects, including without limitation, Scholar Rock&rsquo;s expectations regarding its growth,
strategy, progress and timing of its clinical trials for apitegromab, and other product candidates and indication selection and development
timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical
trial data, and the potential of its product candidates and proprietary platform. The use of words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo;
 &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;future,&rdquo; &ldquo;potential,&rdquo; or &ldquo;continue,&rdquo;
and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based
on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties
include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial, including extension
periods, of apitegromab are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials
of the same product candidate, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA, Scholar Rock&rsquo;s ability
to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline,
the data generated from Scholar Rock&rsquo;s nonclinical and preclinical studies and clinical trials, information provided or decisions
made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock&rsquo;s ability
to obtain, maintain and protect its intellectual property, Scholar Rock&rsquo;s dependence on third parties for development and manufacture
of product candidates including, without limitation, to supply any clinical trials, Scholar Rock&rsquo;s ability to manage expenses and
to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and
new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well
as those risks more fully discussed in the section entitled &quot;Risk Factors&quot; in Scholar Rock&rsquo;s Quarterly Report on Form
10-Q for the quarter ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar
Rock&rsquo;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&rsquo;s
views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press
release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Scholar Rock:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rushmie Nofsinger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">rnofsinger@scholarrock.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@scholarrock.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">857-259-5573</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ariane Lovell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finn Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ariane.lovell@finnpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">media@scholarrock.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917-565-2204&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
<div><a name="tm2218780d1_ex99-2.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>

                    <script>var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"543865",ustr:"",originlat:"0",clientrtt:"606",ghostip:"23.62.181.15",ipv6:false,pct:"10",clientip:"105.119.6.83",requestid:"379bd357",region:"42877",protocol:"",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"379bd357",ai:"505979",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}</script>
                    </HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Confidential and Proprietary Apitegromab Update Data extracted April 7, 2022 Anti - Myostatin Antibody With  Transformative Potential in Patients with  Type 2 and Type 3 SMA</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. (&#8220;Schol ar  Rock&#8221;), including without  limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, inclu din g timing for the initiation of and  reporting results from its clinical trials for  apitegromab , SRK - 181, and other product candidates and indication selection and development timing, its cash  runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinica l o r clinical trial data, and the  potential of its product candidates and proprietary platform. The use of words such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;shou ld, &#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221;  &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended  to  identify such forward - looking  statements  for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. All such forward - looking statements are  based on management's current expectations of future events and are subject to a number of risks and uncertainties that could ca use actual results to differ  materially and adversely from those set forth in or implied by such forward - looking statements. These risks and uncertainties in clude, without limitation, that  preclinical and clinical data, including the results from the Phase 2 trial of  apitegromab or Part A of the Phase 1 trial of SRK - 181, are not predictive of, may be  inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, includin g t he Phase 3 clinical trial of  apitegromab in SMA and Part B of the Phase 1 clinical trial of SRK - 181, respectively, Scholar Rock&#8217;s ability to provide the financial suppo rt, resources and  expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock &#8217;s  nonclinical and preclinical  studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties th at are developing products for  similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#8217;s cu rrent and potential future  collaborations, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including, w ith out limitation, to supply any  clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its busine ss  activities and establish and  maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID - 19  on business operations and  expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Annual Rep ort on Form 10 - K for the year ended  December 31 2021, Quarterly Report on Form 10 - Q for the quarter ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other  important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission.  Any forward - looking stateme nts represent Scholar  Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All informat ion in this press release is as of the  date of the release, and Scholar Rock undertakes no duty to update this information unless required by  law.This presentation and the any accompanying oral  presentation may also contain estimates and other statistical data made by independent parties and by us relating to market s ize and growth and other data  about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weigh t t o such estimates. In addition,  projections, assumptions, and estimates of our future performance and the future performance of the markets in which we compe te  are necessarily subject to  a high degree of uncertainty and risk. &#169; Scholar Rock, Inc. All rights reserved. June 2022. </P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag03.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Agenda 3 SMA Disease Background &amp; Current Treatment Landscape  Apitegromab TOPAZ Extension Period: 24 - Month Data  Apitegromab SAPPHIRE Phase 3 Trial Overview  Business Update </P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag04.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">4 Revolutionary Approach to Regulating Highly Sought - After  Growth Factors Implicated in Devastating Diseases Scholar Rock&#8217;s Target Growth Factor Precursor (Latent Form) Scholar Rock&#8217;s R&amp;D Platform Transform Medical Practice &#8226; Pursue important targets with well - validated  biology but are difficult to drug &#8226; Apply revolutionary approach to tough targets &#8226; Leverage deep insights into structure and  function  &#8226; Engineer antibodies to deliver  differentiated therapeutic profiles (i.e. exquisite selectivity) TOPAZ demonstrated the therapeutic potential of inhibiting the latent forms of growth factors Mature growth factors Prodomain</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag05.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Apitegromab  Shows  Transformative  Potential in  Patients with  Type 2 and 3  SMA &#8226; Spinal Muscular Atrophy (SMA) remains a  devastating and debilitating disease despite the  utilization of SMN therapies &#8226; Motor neuron defect with loss of muscle mass  &#8226; Current therapies target motor neuron  deterioration; muscle - directed therapy may  further improve motor function &#8226; Apitegromab targets myostatin for muscle  function &#8226; Transformative potential in patients with non - ambulatory Type 2/3 SMA thru the TOPAZ  Phase 2 trial &#8226; Exciting potential path forward for  apitegromab with the ongoing SAPPHIRE Phase 3 trial &#8226; Further development in Type 1 SMA planned 5 Apitegromab is an investigational drug candidate being evaluated for the treatment of  spinal muscular atrophy. Apitegromab has not been approved for any use by the FDA or  any other regulatory agency and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag06.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">6 Spinal Muscular Atrophy Overview Type 1 14% Type 2 51% Type 3 35% Global disease with 30,000 - 35,000  affected in U.S. and Europe alone  1,2.3 TOPAZ* 12 - month results  showed transformative  potential in non - ambulatory  Types 2 and 3 patients  Represents ~2/3 of overall  patient population Motor neuron impairment and loss due to SMN genetic deficiency, leading to muscle atrophy and weakness * TOPAZ Phase 2 trial evaluated patients with Type 2 and 3 SMA (did not include Type 1) 1. Lally et al, Orphanet Journal of Rare Diseases, 2017  2. SMA Europe. SMATracker. About SMA. Accessed January 24, 2022. https://smatracker.eu/what - is - spinal - muscular - atrophy.  3. National Organization for Rare Disorders. Spinal muscular atrophy. Accessed January 24, 2022. https://rarediseases.org/rare - dise ases/spinal - muscular - atrophy/.  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s  not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established .</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag07.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Patients with Types 2 and 3 SMA Continue to Experience Major  Functional Deficits Despite Improvement from Nusinersen 7 HFMSE=Hammersmith Functional Motor Scale - Expanded Darras, B., et.al. Nusinersen in later - onset spinal muscular atrophy. Neurology. May 2019; 92 (21) e2492 - e2506.  This third - party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ cl inical trial results. Mean improvement in HFMSE experienced by patients with non - ambulatory Types 2/3 SMA in nusinersen Phase 3 CHERISH trial 3.9 - point increase in HFMSE  from nusinersen 0 20 40 60 80 HFMSE Score at Month 15 Total Possible HFMSE Score  of 66 Patients treated with nusinersen  continue to experience major  functional deficits (4.9 point increase relative to sham control)</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag08.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">HFMSE=Hammersmith Functional Motor Scale - Expanded.  1. Mercuri E, et al. Presented at: World Muscle Society Congress 2020, P. 257 2. Oskoui M, et al. Presented at: 2021 Muscular Dystrophy Association Clinical &amp; Scientific Conference; March 15 - 18, 2021. Poster 80.  This third - party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ cl inical trial results.  Plateauing of HFMSE increases observed following initial  treatment effects for nusinersen Mean (+ SE) Change in HFMSE Total Score From Baseline Analysis Visit, days 1    92 169 253 350 450           690              930           1170         1410         1650 8 7 6 5 4 3 2 1 0 - 1 - 2 - 3 - 4 &lt;1 - point increase in HFMSE  after ~ first year of treatment +3.9 - points +4.6 - points Unmet Need for Motor Function  Gains I nitial treatment CHERISH Chronic maintenance phase SHINE Motor Gains in Patients with Types 2 and 3 SMA on SMN Therapies Appear to  Plateau After Initial Gains Plateau of HFMSE increases observed following initial   treatment effect of  risdiplam , although longer timeframes  currently under investigation  2 Mean Change From Baseline  in HFMSE Total Score &#8224; Visit, months  &#8211; 1 0 1 2 3 4 0 2 4 6 8 10 18 20 22 24 16 14 12 Placebo Risdiplam RISDIPLAM 2 NUSINERSEN 1 Overall population 2 - 25 years old 8</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag09.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Summary of TOPAZ Extension Period: 24 - Month Data  Sustained Benefit and Evidence of Continued Improvement &#9633; Non - Ambulatory Types 2/3 SMA  &#8226; Motor function associated with activities of daily living improved with apitegromab + nusinersen  at 24 months: o Sizable and sustained gains in HFMSE scores observed o Continued increase in Revised Upper Limb Module (RULM) scores observed o Dose response observed over 24 months, with evidence of further motor function gains as low - dose patients switch to high - dose in extension period ( 2 mg/kg to 20 mg/kg) &#9633; Ambulatory Type 3 SMA  &#8226; Stability of Revised Hammersmith Scale (RHS) in patients receiving 20 mg/kg of apitegromab +  nusinersen &#8226; Potential motor function gains in subgroups  &#9633; No serious safety risks identified to date &#8226; Five most common treatment - emergent adverse events (TEAEs) were headache, pyrexia, upper  respiratory tract infection, cough, and nasopharyngitis &#8203; &#8226; Incidence and types of TEAEs were consistent with underlying disease or nusinersen therapy &#9633; Detailed analyses to be presented at Cure SMA (June 2022) 9 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab  has not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been  established.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag10.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Phase 2 Trial Design Apitegromab = nonproprietary name for SRK - 015 HFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised Hammersmith Scale Data on file. Scholar Rock, Inc. Cambridge, MA Ambulatory Patients (Revised Hammersmith Scale) Non - Ambulatory Patients (Hammersmith Functional Motor Scale Expanded) Cohort 1 Cohort 2 Cohort 3 &#8226; N= 23; ages 5 - 21 &#8226; Open - label, single - arm &#8226; 20 mg/kg apitegromab IV Q4W &#8226; 12 - month treatment period &#8226; N= 15; ages 5 - 21 &#8226; Open - label, single - arm &#8226; 20 mg/kg apitegromab IV Q4W &#8226; 12 - month treatment period &#8226; N= 20; ages &#8805;2 &#8226; Double - blind, randomized (1:1)  to 2 mg/kg or 20 mg/kg  apitegromab IV Q4W &#8226; 12 - month treatment period &#8226; Ambulatory Type 3 SMA &#8226; Two subgroups: 1) Receiving nusinersen 2) Apitegromab monotherapy &#8226; Type 2 or Type 3 SMA &#8226; Receiving nusinersen (initiated at age  5 or older) &#8226; Type 2 SMA &#8226; Receiving nusinersen  (initiated before age 5) &#8226; Safety &#8226; Mean change from baseline in RHS &#8226; Safety &#8226; Mean change from baseline in HFMSE &#8226; Safety &#8226; Mean change from baseline in  HFMSE 10</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag11.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Apitegromab is an investigational product candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s not been  approved by any regulatory authority and its safety and efficacy have not been established. &#169; Scholar Rock, Inc. All rights r ese rved. April 2022 TOPAZ Subject Disposition,  Demographics and Baseline  Characteristics *1 patient answered 3 - 4, 1 patient answered &gt;4 , both patients are in Cohort 1 treated with 20 mg/kg +  nusinersen ; data not available for all patients.  &#8224; 1 cohort 1 patient discontinued study in 12M Treatment Period, 1 cohort 1 patient and 1 cohort 2 patient discontinued during  24M Extension Period A. All discontinuations  were for reasons unrelated to study drug. HFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised Hammersmith Scale. Data on File. Scholar Rock, Inc. Cambridge, MA. Ambulatory Patients Cohort 1 NonAmbulatory Patients Cohort 2 Cohort 3 20 mg/kg monotherapy 20 mg/kg +  nusinersen 20 mg/kg +  nusinersen 2 mg/kg +  nusinersen 20 mg/kg +  nusinersen N (dosed) 11 12 15 10 10 Mean age at screening (min, max) 12.1 (7, 19) 13.1 (7, 21) 11.7 (8, 19) 4.1 (2, 6) 3.8 (2, 6) Mean age at SMA diagnosis (min, max) 5.9 (2, 15) 4.5 (2, 15) 3.1 (1, 16) 1.2 (1, 2) 1.2 (1, 3) Female (%) 73% 58% 53% 30% 50% SMN2 Gene Copy* (#, %) 2 1 (9%) 0 (0%) 1 (10%) 1 (10%) 3 4 (36%) 9 (75%) 11 (73%) 8 (80%) 8 (80%) 4 4 (36%) 1 (8%) 2 (13%) 1 (10%) 0 (0%) # of maintenance doses of  nusinersen at  baseline (min, max) N/A 5.6 (2, 8) 5.1 (2, 9) 5.5 (2, 9) 5.4 (3, 8) Discontinuation(s) 0 2 &#8224; 1 &#8224; 0 0 Scoliosis (#, %) 7 (63.6) 4 (33.3) 11 (73.3) 4 (40%) 3 (30%) Contracture(s) (#, %) 6 (54.5) 7 (58.3) 13 (86.7) 8 (80%) 4 (40%) Mean RHS score (min, max) 47.6 (26, 63) 51.3 (43, 62) Mean HFMSE score (min, max) 22.7 (13, 39) 26.1 (12, 44) 23.5 (14, 42) 11</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag12.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Extension Period Overview 12  month 57 of 58 patients  completed primary  treatment period  and enrolled in  second year of  therapy &#8226; 55 of 57 patients completed &#8226; High dose (20 mg/kg) patients  stayed on high dose &#8226; Low dose (2 mg/kg) patients  switched to high dose (20 mg/kg)* &#8226; Four patients had scoliosis surgery  during year 2** 3 rd Year of Therapy &amp; Beyond  24  month 54 of 55 patients remain on treatment  as of June 1, 2022  2 nd Year of Therapy 12 *All ten patients switched from low dose to high dose. Time points varied across individual  patients. ** Three non - ambulatory patients and one ambulatory patient </P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag13.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Significance of Hammersmith Functional Motor Scale Expanded (HFMSE) Validated measure assessing the physical abilities of patients with Types 2/3 SMA o Consists of 33 items graded on a scale of 0 to 2: 0 denotes  unable; 1 denotes performed with modification or  adaptation; and 2 denotes without modification or  adaptation.  o Item scores are summed to give a total score with a  maximum of 66. The higher the total score, the greater the  patient&#8217;s motor function. o Examples of items: o One hand to head in sitting o Rolls supine to prone o Lying to sitting o Four &#8211; point kneeling o Supported standing o Stepping o Ascends 4 stairs with railing Able to touch head  above ear level whilst  maintaining stable  trunk and head  position  Able to roll from  supine to prone over  the right side without  pulling/pushing on  hands O&#8217;Hagen et al. 2007; Glanzman et al. 2011;  Hammersmith Functional Motor Scale Expanded for SMA (HFMSE)  Manual, 2019 Examples of HFMSE items 13</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag14.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Sizable, Sustained Increases in HFMSE Observed At 24 Months of Apitegromab Pooled Non - Ambulatory Patients Data on File. Scholar Rock, Inc. Cambridge, MA . Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients treated with th e  lower dose 2 mg/kg and does not exclude any patients who missed  apitegromab doses due to COVID - 19 site access restrictions. Error bars  represent standard error of the mean (SEM). Values in parentheticals represent 95% confidence interval.  14 Age 2 - 21  Age 2 - 12  3.6 (1.2, 6.0) n=32 4.0 (1.5, 6.5) n=29 n=29 n=35 6 months 12 months 24 months 6 months 12 months 24 months Baseline Baseline 1 2 3 4 5 6 7 Mean change from baseline in HFMSE  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established. 3.4 (1.8, 5.0) n=23 4.6 (1.7, 7.6) n=24 4.6 (1.8, 7.4) n=26 2.8 (1.4, 4.1) n=29</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag15.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Reported Impact of Scoliosis Surgery on Motor Abilities in SMA o The vast majority of patients in this peer - reviewed study lost &gt;3 pts on the HFMSE as  assessed at least 3 months post - surgery o 14/17 participants lost &gt;3 points (mean change  =  - 12.1, SD = 8.9) on the HFMSE, representing a  functionally meaningful change   o 3/17 participants had minimal HFMSE changes  within  &#177; 2 points (mean change =  - 0.7),  representing no change or stability o 0/17 participants had improvement greater than  2 points post - surgery Post - Surgery HFMSE scores Type 2/3 SMA ( Dunaway Young et al. 2020) 15</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag16.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Sizable, Sustained Increases in HFMSE Observed At 24 Months of Apitegromab Pooled Non - Ambulatory Patients Excluding Data Post Scoliosis Surgery Data on File. Scholar Rock, Inc. Cambridge, MA.  16 6 months 12 months 24 months 6 months 12 months 24 months Baseline Baseline Age 2 - 12  3.6 (1.2, 6.0) n=32 n=29 n=35 1 2 3 4 5 6 7 Age 2 - 21  This analysis excludes from the Observed Case Analysis any HFMSE data following scoliosis surgery in TOPAZ. Of the three non - amb ulatory  patients who had scoliosis surgery, data from one was excluded and the other two did not have valid HFMSE assessments. Error  bar s  represent SEM. Values in parentheticals represent 95% confidence interval.  Mean change from baseline in HFMSE  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established. 2.8 (1.4, 4.1) n=29 5.2 (2.3, 8.0) n=23 3.4 (1.8, 5.0) n=23 4.4 (2.0, 6.9) n=28 4.6 (1.8, 7.4) n=26</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag17.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Strong Evidence of Dose Response Observed Over 24 Months  Further Supported by Data from Low Dose to High Dose Switch 20 mg/kg throughout Switched from  2 mg/kg to 20 mg/kg Dose - switching period This analysis excludes from the Observed Case Analysis the HFMSE data attained post - scoliosis surgery during TOPAZ. Error bars r epresent SEM.  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established. 17 Mean Change from Baseline in HFSME Scores Over Time (Cohort 3) Excludes data after scoliosis surgery</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag18.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0 3 0 8 3 3 6 3 6 4 3 9 2 4 2 0 4 4 8 4 7 6 5 0 4 5 3 2 5 6 0 5 8 8 6 1 6 6 4 4 6 7 2 7 0 0 7 2 8 1 10 100 1000 10000 Time (days) M e a n   ( &#177; S D )   L a t e n t   M y o s t a t i n C o n c e n t r a t i o n   ( n g / m L ) TOPAZ Cohort 1 (20 mg/kg) TOPAZ Cohort 2 (20 mg/kg) TOPAZ Cohort 3 (20 mg/kg) TOPAZ Cohort 3 (2 mg/kg) 0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0 3 0 8 3 3 6 3 6 4 3 9 2 4 2 0 4 4 8 4 7 6 5 0 4 5 3 2 5 6 0 5 8 8 6 1 6 6 4 4 6 7 2 7 0 0 7 2 8 1 10 100 1000 10000 Time (days) M e a n   ( &#177; S D )   S R K - 0 1 5 C o n c e n t r a t i o n   (  g / m L ) TOPAZ Cohort 1 (20 mg/kg) TOPAZ Cohort 2 (20 mg/kg) TOPAZ Cohort 3 (20 mg/kg) TOPAZ Cohort 3 (2 mg/kg) &#8226; Well - behaved PK profile consistent with that  commonly observed with monoclonal antibodies &#8226; Drug exposure was dose proportional PK and PD Data are Consistent With Clinically Observed  Dose Response Pharmacokinetics* (PK) Target Engagement [Pharmacodynamics (PD)] *Starting at day 28, measures are  predose trough levels. Data on File. Scholar Rock, Inc. Cambridge, MA. &#8226; Target engagement by  apitegromab was confirmed &#8226; Low - dose (2 mg/kg) yielded lower level of target  engagement and did not achieve full target saturation 18 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal  muscular atrophy. Apitegromab has not been approved for any use by the FDA or any other  regulatory agency and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag19.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Significance of the Revised Upper Limb Module (RULM) Evaluates Motor Performance in Upper Limbs  o Evaluated upper limb tasks correspond to ability to perform  everyday activities  o Exc ept for  1 activity with a binary score, the items are  scored 0 to 2: 0 denotes unable; 1 denotes able with  modification; and 2 denotes able with no difficulty o Maximum score of 37 points (19 task items) o Examples of items: o Putting a coin into a cup o Elevating a cup to mouth o Picking up a coin o Bringing hand to shoulder o Lifting up weighted objects o Opening a zip lock bag  o Drawing a line on paper Able to bring token to cup placed vertically at shoulder  height Brings weight at eye level using two hands Mazzone et al. 2017; Pierzchlewicz et al. 2021;  Revised Upper Limb Module for SMA Manual, 2014  Examples of RULM items 19</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag20.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Continued Increase in RULM Observed at  24 Months of Apitegromab  Pooled Non - Ambulatory Patients  Data on File. Scholar Rock, Inc. Cambridge, MA. Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients  treated with the lower dose 2 mg/kg and does not exclude any patients who missed  apitegromab doses due to COVID - 19  site access restrictions. Error bars represent SEM. Values in parentheticals represent 95% confidence interval.  Age 2 - 21  Age 2 - 12  12 months 24 months 6 months 0.2 ( - 0.7, 2.4) n=22 3 2 1 0 20 1.2 (0.1, 2.4) n=25 Baseline n=28 0.6 ( - 0.2, 1.4) n =28 Baseline 6 months 12 months 24 months n=28 n=34 Mean change from baseline in RULM  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s  not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established . 1.9 (0.8, 3.0) n=33 1.8 (0.6, 3.0) n=28 1.3 (0.2, 2.3) n=31</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag21.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Continued  Increase in RULM Observed at 24 Months of Apitegromab  Pooled Non - Ambulatory Patients Excluding Data Post Scoliosis Surgery Data on File. Scholar Rock, Inc. Cambridge, MA. This analysis excludes data from 3 non - ambulatory patients after their scoliosis surgery during TOPAZ from the Observed  Case Analysis. Error bars represent SEM. Values in parentheticals represent 95% confidence interval.  Age 2 - 21  Age 2 - 12  24 months 12 months 6 months n=28 0 1 2 3 21 0.2 ( - 0.7, 1.1 ) n=22 Baseline 24 months 12 months 6 months 0.6 ( - 0.2, 1.4 ) n=28 Baseline n=34 Mean change from baseline in RULM  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s  not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established . 2.2 (1.0, 3.5) n=25 2.3 (1.2, 3.4) n=30 1.2 (0.1, 2.4) n=25 1.3 (0.2, 2.3) n=31</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag22.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Correlation of HFMSE to RULM Increased Over 24 Months Pooled Non - Ambulatory Patients  -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 1011 1213 14 1516 1718 19 20 HFMSE Change from Baseline at EXT14/Day 728 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 R U L M   C h a n g e   f r o m   B a s e l i n e   a t   E X T 1 4 / D a y   7 2 8 Regression95% Confidence Limits RULM and HFMSE Change from baseline at 24 months Observed Cases -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 1011 1213 14 1516 1718 19 20 HFMSE Change from Baseline at V15/Day 364 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 R U L M   C h a n g e   f r o m   B a s e l i n e   a t   V 1 5 / D a y   3 6 4 Regression95% Confidence Limits RULM and HFMSE Change from baseline at 12 months Observed Cases The observation that the majority of patients in this analysis experienced gains in both the HFMSE  and RULM over 24 months further supports the therapeutic potential of apitegromab. r = 0.28 p = 0.1216 n= 31 r = 0.58 p = 0.0011 n=28  22 This analysis is based on the Observed Case Analysis population. The 12 - month  graph displays all patients who had a valid measurement at visit 15 (Day 364) and  the 24 - month graph displays all patients who had a valid measurement at extension  visit 14 (Day 728). Apitegromab is an investigational drug candidate being evaluated for the  treatment of spinal muscular atrophy. Apitegromab has not been  approved for any use by the FDA or any other regulatory agency and its  safety and efficacy have not been established. &#8220; &#8221; - Basil Darras, MD  Associate Neurologist - in - Chief, Boston Children&#8217;s Hospital;  Professor of Neurology, Harvard Medical School;  TOPAZ trial Investigator</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag23.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Therapeutic Potential of Apitegromab Observed in the Ambulatory Type  3  SMA Cohort at 24 Months  Ambulatory Patients (Revised Hammersmith Scale; RHS) 24 Month Analysis Cohort 1 20 mg/kg pooled  (n=21) 20 mg/kg monotherapy (n=11) 20 mg/kg + nusinersen  (n=10) Mean change from baseline (95% CI) - 1.8 ( - 4.7, 1.1) - 2.8 ( - 8.4, 2.8) - 0.7 ( - 3.1, 1.7) # (%) pts achieving &#8805;1 - pt increase 9/21 (42.9%) 5/11 (45.5%) 4/10 (40%) # (%) pts achieving &#8805;3 - pt increase 5/21 (23.8%) 3/11 (27.3%) 2/10 (20%) Observed Case Analysis includes all patients who had a valid measurement at E14 (Day 728). Inclusive of data from 3 patients in apitegromab monotherapy who lost ability to ambulate. 23 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular  atrophy. Apitegromab has not been approved for any use by the FDA or any other regulatory agency  and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag24.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">No Serious Safety Risks Identified Over 24 Months of  Apitegromab Treatment  Treatment - Emergent Adverse Events (TEAEs)* 2 mg/kg dose  (N=10) n (%) 20 mg/kg dose  (N=48) n (%) Total (N=58) n (%) Any TEAE 10 (100) 45 (93.8) 55 (94.8) Any Serious TEAE 3 (30) 11 (22.9) 14 (24.1) Any TEAE leading to study drug discontinuation 0 (0.0) 1 (2.1) 1 (1.7) Any Grade 3 (severe) or higher TEAE 2 (20) 9 (18.8) 11(19) &#9633; The incidence and types of treatment - emergent AEs were consistent with the underlying disease or nusinersen therapy &#9633; The 5 most common treatment - emergent AEs were headache, pyrexia, upper respiratory tract infection, cough, and nasopharyngitis &#9633; No deaths or suspected unexpected serious adverse reactions (SUSARs) reported &#9633; Adverse events continue to be reported as mostly mild to moderate in severity, as observed in the 12 - month analysis &#9633; No serious safety  risks identified to  date *Notes: % = 100 x n/N (n=incidence) Treatment - emergent adverse events (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to the administration of study drug and worsen in severity/grade or relationship to investigational medication after the administrat ion of study drug.  Data collected for safety events over the 24 - month period and includes patients who switched from 2 mg/kg to 20 mg/kg.  Data on file,  extracted on April 7, 2022. Scholar Rock, Inc. Cambridge, MA 24 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag25.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Summary of TOPAZ Extension Period: 24 - Month Data  Sustained Benefit and Evidence of Continued Improvement &#9633; Non - Ambulatory Types 2/3 SMA  &#8226; Motor function associated with activities of daily living improved with apitegromab + nusinersen  at 24 months: o Sizable and sustained gains in HFMSE scores observed o Continued increase in Revised Upper Limb Module (RULM) scores observed o Dose response observed over 24 months, with evidence of further motor function gains as low - dose patients switch to high - dose in extension period ( 2 mg/kg to 20 mg/kg) &#9633; Ambulatory Type 3 SMA  &#8226; Stability of Revised Hammersmith Scale (RHS) in patients receiving 20 mg/kg of apitegromab +  nusinersen &#8226; Potential motor function gains in subgroups  &#9633; No serious safety risks identified to date &#8226; Five most common treatment - emergent adverse events (TEAEs) were headache, pyrexia, upper  respiratory tract infection, cough, and nasopharyngitis &#8203; &#8226; Incidence and types of TEAEs were consistent with underlying disease or nusinersen therapy &#9633; Detailed analyses to be presented at Cure SMA (June 2022) 25 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab  has not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been  established.</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag26.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Ongoing SAPPHIRE Phase 3 Trial Overview &#8226; Randomized, double - blind, placebo - controlled, parallel arm design &#8226; Enrolling patients on SMN therapy (nusinersen or  risdiplam ) &#8226; Primary efficacy endpoint: mean HFMSE change from baseline at 12 months &#8226; Study start - up activities commenced Apitegromab (20 mg/kg IV q4w) + SMN upregulator Main  Population Patients (age 2 - 12)  with non - ambulatory  Types 2 and 3 SMA 52 weeks treatment Apitegromab (10 mg/kg IV q4w) + SMN upregulator Placebo + SMN upregulator N = 52 N = 52 N = 52 26</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag27.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">SAPPHIRE Details Main population Endpoints Analysis Additional Data  Opportunities &#8226; Primary efficacy: HFMSE  &#8226; Additional efficacy measures: RULM, WHO, other outcome measures  &#8226; Safety, PK/PD, ADA &#8226; Topline readout based of main efficacy population (age 2 - 12) is apitegromab 20 mg/kg* vs.  placebo &#8226; Interim analysis opportunity when &#8805; 50% of patients in main efficacy population have  completed 12 months &#8226; Exploratory population (age 13 - 21), in patients using SMN therapy; focused upon safety &amp;  exploratory efficacy (n=48; 2:1 randomization between apitegromab 20 mg/kg vs placebo) &#8226; Separate open - label extension study (after patients complete 12 - month period); focused  upon safety &amp; exploratory long - term efficacy &#8226; Age 2 - 12, non - ambulatory Type 2 and Type 3 SMA &#8226; Maintenance phase of SMN therapy (nusinersen &#8805;10 months;  risdiplam &#8805; 6 months) &#8226; Stratified randomization to ensure balanced allocation: 1) age at SMN Rx initiation (age &lt; 5  vs age  &gt; 5)  2) SMN Rx (nusinersen vs. risdiplam) *To control type I error caused by multiple comparisons, the efficacy analysis will first compare the apitegromab 20 mg/kg  arm against placebo before any testing of apitegromab 10 mg/kg against placebo. PK/PD=pharmacokinetics and pharmacodynamics; ADA=anti - drug antibodies  27</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag28.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Focused Pipeline of Novel Product Candidates 28 Discovery - stage pipeline focused on the selective modulation of growth factor signaling APITEGROMAB SRK - 181 A selective inhibitor of myostatin activation being developed as the potential  first muscle - directed therapy for the treatment of spinal muscular atrophy  (SMA) in multiple clinical trials &#8226; Phase 2 TOPAZ study (extension portion ongoing) &#8226; Phase 3 SAPPHIRE trial A selective inhibitor of latent TGF&#946;1 activation being developed with the aim  of overcoming primary resistance to and increasing the number of patients  who may benefit from checkpoint inhibitor therapy &#8226; Potential to become the next transformative therapy for cancer  patients &#8226; Phase 1 DRAGON (Part B ongoing) Potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular  disorders, cancer, and fibrosis Phase 3 Pivotal Trial  Phase 1 Proof of Concept  Trial  28</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag29.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Key Investment Highlights 29 &#8226; Designed to discover and  develop  monoclonal  antibodies that can  modulate growth factors  with extraordinary  selectivity &#8226; Designed to overcome the  challenges  that have  plagued traditional  approaches by targeting  the precursor or latent  forms of growth factors &#8226; Apitegromab (Phase 3) :  potentially transformative  therapy to improve motor  function for patients with  SMA &#8226; SRK - 181 (Phase 1) :  potential to shift the  treatment landscape for  cancer patients with CPI  resistance  &#8226; Discovery - stage pipeline :  focus on myostatin and  TGF&#946; Proprietary Platform Robust Pipeline Phase 3 Pivotal Trial  Phase 1 PoC Trial  Financing Announced Today:  - Fully Funds Sapphire, Phase 3 Pivotal  Trial, Continued Advancement of Part B  Dragon Trial - Runway Extended into 2025 29</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag30.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">30 Appendix </P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag31.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Strong Evidence of Dose Response Observed Over 24 Months Further Supported by Data from Low Dose to High Dose Switch  31 Most patients in Cohort 3 who switched from  2 mg/kg to 20 mg/kg continued to show HFMSE improvement Study day is relative to the date of the first dose of 20 mg/kg Study Day Patient with  scoliosis surgery  Rapid increase  Benefit maintained through  24 - month timepoint  Gradual increases of HFMSE  at 2 mg/kg Continued  improvement  after switch  Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag32.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Cohort 3: Mean RULM Score Change Over Time RULM trended  up in low dose arm patients after switch to high dose All patients in Cohort 3  switched from 2 mg/kg to  20 mg/kg 1 of 9 patients in Cohort 3  switched from 2 mg/kg to  20 mg/kg 9 of 10 patients in Cohort 3  switched from to 2 mg/kg to  20 mg/kg Figure 14.2.1.3.1 Mean (+/- 1 SE) change from baseline in RULM total score over time  Sensitivity Analysis: Excluding measurements after scoliosis surgery  Cohort 3      32 Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients tre ate d with the lower  dose 2 mg/kg and does not exclude any patients who missed  apitegromab doses due to COVID - 19 site access restrictions. Error bars represent  standard error of the mean (SEM). Error bars represent SEM. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s  not been approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established . Mean Change from Baseline in RULM Scores Over Time (Cohort 3) Excludes data after scoliosis surgery</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag33.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">4 of 10 patients in Cohort 3 switched  from 2 mg/kg to 20 mg/kg  9 of 10 patients in  Cohort 3 switched  from 2 mg/kg to  20 mg/kg All patients in  Cohort 3 switched  from 2 mg/kg to  20 mg/kg Cohort 3 2 mg/kg Timing Patient Conversion Timeline to 20 mg/kg: &#8226; Day 560: 105 - 304, 110 - 301, 110 - 302, and 114 - 301 &#8226; Day 644: 105 - 301, 107 - 302, 118 - 301, 302 - 301, and 501 - 301 &#8226; Day 700: 103 - 301 0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0 3 0 8 3 3 6 3 6 4 3 9 2 4 2 0 4 4 8 4 7 6 5 0 4 5 3 2 5 6 0 5 8 8 6 1 6 6 4 4 6 7 2 7 0 0 7 2 8 1 10 100 1000 10000 Time (days) M e a n   ( &#177; S D )   S R K - 0 1 5 C o n c e n t r a t i o n   (  g / m L ) TOPAZ Cohort 1 (20 mg/kg) TOPAZ Cohort 2 (20 mg/kg) TOPAZ Cohort 3 (20 mg/kg) TOPAZ Cohort 3 (2 mg/kg) 0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0 3 0 8 3 3 6 3 6 4 3 9 2 4 2 0 4 4 8 4 7 6 5 0 4 5 3 2 5 6 0 5 8 8 6 1 6 6 4 4 6 7 2 7 0 0 7 2 8 1 10 100 1000 10000 Time (days) M e a n   ( &#177; S D )   S R K - 0 1 5 C o n c e n t r a t i o n   (  g / m L ) TOPAZ Cohort 1 (20 mg/kg) 0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0 3 0 8 3 3 6 3 6 4 3 9 2 4 2 0 4 4 8 4 7 6 5 0 4 5 3 2 5 6 0 5 8 8 6 1 6 6 4 4 6 7 2 7 0 0 7 2 8 1 10 100 1000 10000 Time (days) M e a n   ( &#177; S D )   S R K - 0 1 5 C o n c e n t r a t i o n   (  g / m L ) TOPAZ Cohort 3 (20 mg/kg) PK Data Consistent With Clinically Observed Dose Response 33 Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab ha s n ot been  approved for any use by the FDA or any other regulatory agency and its safety and efficacy have not been established.</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag34.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">TOPAZ Extension Period: 24 - Month Patient Disposition  34 Cohort 1 Ambulatory  Non &#8211; Ambulatory  Cohort 2 Cohort 3 Total  # Non - Ambulatory Patients  (2 - 21) 15 20 35 # Non - Ambulatory Patients  (2 - 12) 9 20 29 Dropped Out (0 - 12 M) 1 0 0 0 Dropped Out (12 - 24 M) 1 1 1 Not Having Valid HFMSE  testing at Month 24 Not applicable 5* 1** 6 Not Having RULM at Month 24 Not applicable 2*** 1**** 3 # of patients  scoliosis surgery   1 2***** 1 3 *Includes 1 patient who withdrew from study; 1 patient off schedule due to scheduled surgery; 1 patient who had hip pain; 1 p ati ent with femur fracture; and 1 patient who  refused to be in supine position. **Patient with bilateral lower extremity cast ***Includes  1 patient withdrew from study, and 1 patient off schedule due to planned surgery. ****Patient was too young for RULM at baseline and RULM was not conducted at following visit. *****Patients did not have valid HFMSE test at 24 months. 34</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag35.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Overall Safety and Tolerability Profile Over 24 Months of  Treatment: Serious TEAEs 35 &#8226; Fourteen patients experienced a serious TEAE, all assessed by the respective trial investigator as  unrelated to  apitegromab : o One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to adenoidal hypertrophy and  tonsillar hypertrophy to perform scheduled adenotonsillectomy (Grade 2). Events resolved without  sequelae. o Two patients treated with 20 mg/kg dose (both Cohort 1) presented with gait inability considered a  significant disability (both Grade 3). Events remain ongoing. o One patient treated with 20 mg/kg dose (Cohort 1) was hospitalized with post lumbar puncture syndrome  (Grade 2). Event resolved without sequelae. o One patient treated with 20 mg/kg dose (Cohort 1) was hospitalized due to viral upper respiratory tract  infection (Grade 2). Event resolved without sequelae. o Five patients treated with 20 mg/kg dose (one from Cohort 1, three from Cohort 2, and one from Cohort  3) were hospitalized for spinal fusion surgery/ scoliosis/ scoliosis surgery (all Grade 3). All events resolved  without sequelae. o One patient treated with 20 mg/kg dose (Cohort 1) was hospitalized due to bilateral developmental hip  dysplasia and left hip dislocation (both Grade 3). Events resolved without sequelae. o One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to hip dislocation (Grade 3). Event  resolved with sequelae (anxiety and post - operative pain). o One patient treated with 20 mg/kg dose (Cohort 3) was hospitalized due to respiratory syncytial virus  infection (Grade 2). Events resolved without sequelae. o One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to vomiting and pneumonia  (Grade 3). Events resolved without sequelae.</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/a2b98c3034c56a085e0b8e2a2a89da4e-tm2218780d1_ex99-2imag36.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Overall Safety and Tolerability Profile Over 24 Months of  Treatment: Non - Serious Grade 3 Events 36 &#8226; Four patients presented with non - serious Grade 3 events, all assessed by the respective trial  investigator as unrelated to  apitegromab : o One patient treated with 20 mg/kg dose (Cohort 1) presented with post lumbar puncture syndrome.  Event resolved without sequelae. o One patient treated with 20 mg/kg dose (Cohort 2) presented with worsening of scoliosis. Event  resolved (with surgery, reported as serious, above) without sequelae. o One patient treated with 20 mg/kg dose (Cohort 2) presented with osteopenia. Events remains ongoing. o One patient treated with 2 mg/kg (Cohort 3) presented with two instances of hypoglycemia and one  instance of metabolic acidosis. All events resolved without sequelae. o One patient (Cohort 1) discontinued from the trial due to Grade 2 muscle fatigue that started prior to  initiation of dosing with study drug; assessed by the trial investigator as unrelated to  apitegromab .</P>

<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8871\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
